BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.
BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.
The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.
BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.